LAS VEGAS--(BUSINESS WIRE)--Nutri Pharmaceuticals Research, Inc. (Pink Sheets: NRPR) announced today that it has been selected to collaborate on the development of a dry formulation for Triheptanoin by Dr. Charles Roe, Medical Director of the Institute of Metabolic Disease at Baylor University Medical Center, Dallas. Triheptanoin is a unique medium-odd chain triglyceride that has provided significant benefit to many patients with inherited biochemical disorders. Clinical features of these disorders can include muscle weakness, pain and breakdown of muscle tissue (rhabdomyolysis), and cardiomyopathy (disease of the heart muscle) all resulting from the lack of proper energy production within the cells.
